OncoMatch/Clinical Trials/NCT07116486

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

Is NCT07116486 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for hepatocellular carcinoma.

Phase 1RecruitingM.D. Anderson Cancer CenterNCT07116486Data as of May 2026

To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify